EcoDrugPlus

Amyloid Beta Precursor Protein

Ensembl ID : ENSCLAG00000008908
Gene Symbol: APP
2 Cross references
279 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSCLAG00000009155
Gene Symbol: AR
2 Cross references
277 Possible Orthologues:

Angiotensin I Converting Enzyme

Ensembl ID : ENSCLAG00000004440
Gene Symbol: ACE
2 Cross references
92 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSCLAG00000004411
Gene Symbol: AGTR1
3 Cross references
213 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSCLAG00000017599
Gene Symbol: AGTR2
3 Cross references
195 Possible Orthologues:

Apelin Receptor

Ensembl ID : ENSCLAG00000017677
Gene Symbol: APLNR
2 Cross references
172 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSCLAG00000013532
Gene Symbol: APH1A
3 Cross references
138 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSCLAG00000014885
Gene Symbol: APH1B
2 Cross references
193 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSCLAG00000001002
Gene Symbol: APEX1
2 Cross references
214 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s Type

Ensembl ID : ENSCLAG00000009075
Gene Symbol: ALOX12
3 Cross references
198 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSCLAG00000001854
Gene Symbol: ALOX5
2 Cross references
223 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSCLAG00000005620
Gene Symbol: ALOX5AP
2 Cross references
201 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).